XT
CRSP icon

XTX Topco’s CRISPR Therapeutics CRSP Stock Holding History

XTX Topco’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6M Buy
29,279
+22,536
+334% +$1.19M 0.02% 1337
2026
Q1 		$321K Buy
+6,743
New +$356K 0.01% 2430
2025
Q2 		– Sell
-10,907
Closed -$371K – 2494
2025
Q1 		$371K Buy
10,907
+1,988
+22% +$84.3K 0.02% 1247
2024
Q4 		$351K Sell
8,919
-21,103
-70% -$996K 0.03% 1083
2024
Q3 		$1.41M Buy
30,022
+22,402
+294% +$1.14M 0.1% 276
2024
Q2 		$412K Sell
7,620
-3,071
-29% -$178K 0.04% 755
2024
Q1 		$729K Buy
10,691
+6,827
+177% +$489K 0.1% 279
2023
Q4 		$242K Sell
3,864
-18,093
-82% -$1M 0.05% 804
2023
Q3 		$997K Buy
21,957
+6,583
+43% +$340K 0.17% 97
2023
Q2 		$863K Buy
+15,374
New +$872K 0.15% 130
2022
Q3 		– Sell
-5,233
Closed -$318K – 1143
2022
Q2 		$318K Buy
+5,233
New +$308K 0.13% 251
2021
Q4 		– Sell
-7,248
Closed -$811K – 740
2021
Q3 		$811K Buy
7,248
+2,670
+58% +$335K 0.27% 79
2021
Q2 		$741K Buy
+4,578
New +$557K 0.25% 77

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

XTX Topco's CRSP Position: Q2 2026 in Review

XTX Topco increased its CRISPR Therapeutics (CRSP) stake by 334% in Q2 2026, buying an estimated $1.19M and bringing the position to 29,279 shares worth $1.6M. The position accounts for 0.02% of the portfolio, ranked #1337.

XTX Topco first reported a position in CRSP in Q2 2021 and has held it in 13 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • XTX Topco held 29,279 shares of CRISPR Therapeutics worth $1.6M as of Q2 2026.
  • XTX Topco bought 22,536 CRISPR Therapeutics shares in Q2 2026, an estimated $1.19M.
  • CRISPR Therapeutics made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1337 holding.
  • XTX Topco first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 13 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.